Press release - DelveInsight Business Research LLP - Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2024 (Updated) - published on openPR.com
Efficacy and safety of the two formulations were directly compared in a randomized, controlled, double-blind study of men with AGA conducted in Brazil.
Antibodies targeting the CXCL12 protein show potential to promote hair growth in conditions like androgenic alopecia (AGA) and alopecia areata (AA), offering hope for new treatment options.
The hormones testosterone and estrogen play a vital role in keeping our hair healthy. Our hair can reflect our internal health. Stress and traumatic events can lead to hair loss.